These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
9. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist. Mitrzyk BM Pharmacotherapy; 2008 Oct; 28(10):1243-54. PubMed ID: 18823220 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741 [TBL] [Abstract][Full Text] [Related]
12. Modern Collapse Therapy for Pulmonary Tuberculosis. Krasnov DV; Skluev SV; Petrova YK; Skvortsov DA; Krasnov VA; Felker IG; Grischenko N Thorac Surg Clin; 2019 Feb; 29(1):47-58. PubMed ID: 30454921 [TBL] [Abstract][Full Text] [Related]
14. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Payen MC; De Wit S; Martin C; Sergysels R; Muylle I; Van Laethem Y; Clumeck N Int J Tuberc Lung Dis; 2012 Apr; 16(4):558-60. PubMed ID: 22325421 [TBL] [Abstract][Full Text] [Related]
15. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012. Chang KC; Yew WW Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408 [TBL] [Abstract][Full Text] [Related]
16. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Skrahin A; Ahmed RK; Ferrara G; Rane L; Poiret T; Isaikina Y; Skrahina A; Zumla A; Maeurer MJ Lancet Respir Med; 2014 Feb; 2(2):108-22. PubMed ID: 24503266 [TBL] [Abstract][Full Text] [Related]
17. Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. Masjedi MR; Tabarsi P; Baghaei P; Jalali S; Farnia P; Chitsaz E; Amiri M; Mansouri D; Velayati AA Int J Infect Dis; 2010 May; 14(5):e399-402. PubMed ID: 19818664 [TBL] [Abstract][Full Text] [Related]
18. Extensively drug-resistant tuberculosis: experience at the Tuberculosis Research Centre, Chennai, India. Thomas A; Joseph P; Nair D; Rao DV; Rekha VV; Selvakumar N; Jaggarajamma K; Balambal R Int J Tuberc Lung Dis; 2011 Oct; 15(10):1323-5. PubMed ID: 22283888 [TBL] [Abstract][Full Text] [Related]
19. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. Schaaf HS; Willemse M; Donald PR Pediatr Infect Dis J; 2009 Aug; 28(8):748-50. PubMed ID: 19633523 [TBL] [Abstract][Full Text] [Related]
20. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Kliiman K; Altraja A Eur Respir J; 2009 May; 33(5):1085-94. PubMed ID: 19164345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]